Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04294225 · ClinicalTrials.gov registry record · Phase 2
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 161
- Enrollment target
NCT04294225: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT04294225 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 161 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04294225, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 161 participants
- Enrollment target
Study Summary
This phase II trial studies how well anastrozole and letrozole after surgery work in treating patients with stage I-III breast cancer. Drugs, such as anastrozole and letrozole, may stop the growth of tumor cells by decreasing the amount of estrogen made by the body. Giving anastrozole and letrozole after surgery may prevent breast cancer from coming back (recurrence).
Interventions
- DRUG Anastrozole
- DRUG Letrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2020-04-28 |
| Est. Completion | 2022-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04294225
The ClinicalTrials.gov registry entry for NCT04294225 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anastrozole is the first listed.
NCT04294225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04294225 about?
NCT04294225 is a clinical study titled "Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer". This phase II trial studies how well anastrozole and letrozole after surgery work in treating patients with stage I-III breast cancer. Drugs, such as anastrozole and letrozole, may stop the growth of tumor cells by decreasing the amount of estrogen made by the body. Giving anastrozole and letrozole ...
What is the current status of trial NCT04294225?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 161 participants. The study started on 2020-04-28. Estimated completion is 2022-12-12.
What interventions are being tested in trial NCT04294225?
The interventions under investigation include: Anastrozole (DRUG), Letrozole (DRUG).
Who is sponsoring clinical trial NCT04294225?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.